FDA Approves BUPRENORPHINE AND NALOXONE — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. received final FDA approval on January 21, 2026, for its buccal buprenorphine and naloxone tablets, slated to compete against established opioid agonist treatments and potentially broaden access to the growing market for non-narcotic addiction therapies.